Please use this identifier to cite or link to this item:
|Title:||Class III ß-Tubulin Isotope Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Docetaxel|
|Authors:||GALMARINI Carlos M.; TREILLEUX Isabelle; CARDOSO Fatima; BERNARD-MARTY Chantal; DURBECQ Virginie; GANCBERG David; BISSERY Marie-Christine; PAESMANS Marianne; LARSIMONT Denis; PICCART Martine J.; DI LEO Angelo; DUMONTET Charles|
|Citation:||CLINICAL CANCER RESEARCH vol. 14 no. 14 p. 4511-4516|
|Publisher:||AMER ASSOC CANCER RESEARCH|
|Type:||Articles in periodicals and books|
|Abstract:||Evaluate microtubule-associated variables as potential predictors of response and clinical outcome in patients with advanced breast cancer receiving single-agent docetaxel or doxorubicin chemotherapy. Expression of total alpha- or beta-tubulin, classes II to IV beta-tubulin isotypes, and tau protein was evaluated by immunohistochemistry on the primary breast cancer. Patients with "high" expression of class III beta-tubulin isotype had a higher probability of response to docetaxel than to doxorubicin treatment. This study suggests that the superiority of docetaxel over doxorubicin seems restricted to the subgroup of patients with "high" expression of class III beta-tubulin isotype.|
|JRC Institute:||Health, Consumers and Reference Materials|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.